Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Pérez-Alós L, Hansen C, Almagro Armenteros J, Madsen J, Heftdal L, Hasselbalch R, Pries-Heje M, Bayarri-Olmos R, Jarlhelt I, Hamm S, Møller D, Sørensen E, Ostrowski S, Frikke-Schmidt R, Hilsted L, Bundgaard H, Nielsen S, Iversen K, Garred P. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nature Communications 2023, 14: 5624. PMID: 37699890, PMCID: PMC10497567, DOI: 10.1038/s41467-023-41342-2.Peer-Reviewed Original ResearchConceptsImmune responseImmune imprintingOmicron infectionIgA responsesPrimary infectionSARS-CoV-2 immune responseSARS-CoV-2 infectionT cell immune responsesBreakthrough infection riskRobust humoral responseT cell responsesBNT162b2 vaccineHybrid immunityBooster vaccinationPrevious immunityVaccinated individualsHumoral responseLow IgGViral exposurePrevious infectionSubsequent reinfectionHigh riskVaccinationOmicron variantFuture infectionsEvidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriodShort-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
Madsen J, Holm B, Pérez-Alós L, Bayarri-Olmos R, Rosbjerg A, Fogh K, Pries-Heje M, Møller D, Hansen C, Heftdal L, Hasselbalch R, Hamm S, Frikke-Schmidt R, Hilsted L, Nielsen S, Iversen K, Bundgaard H, Garred P. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination. Microbiology Spectrum 2023, 11: e04947-22. PMID: 36877077, PMCID: PMC10101069, DOI: 10.1128/spectrum.04947-22.Peer-Reviewed Original ResearchSARS-CoV-2Salivary immunityIgG levelsBNT162b2 vaccinationFirst vaccinationSARS-CoV-2-infected individualsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 vaccinationSARS-CoV-2 IgGSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Prospective observational studyTime pointsSerum IgG levelsHigher IgG levelsSyndrome coronavirus 2Copenhagen University HospitalEffect of vaccinationHealth care professionalsBNT162b2 vaccineHybrid immunitySystemic vaccinationDetectable IgGSalivary IgG
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply